Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simone Diermeier-Daucher

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Current Protocols in Cell Biology|September 21, 2010
Dynamic proliferation assessment in flow cytometrySimone Diermeier-Daucher, Gero Brockhoff
Current Protocols in Cytometry|September 5, 2008
Flow cytometric FRET analysis of ErbB receptor tyrosine kinase interactionSimone Diermeier-Daucher, Gero Brockhoff
Annals of the New York Academy of Sciences|July 4, 2008
Flow cytometric FRET analysis of erbB receptor interaction on a cell-by-cell basisSimone Diermeier-Daucher, Max Hasmann, Gero Brockhoff
Mabs|July 24, 2012
Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signalingSimone Diermeier-Daucher, Olaf Ortmann, Stefan Buchholz, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|July 26, 2011
Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factorsSimone Diermeier-Daucher, Stefanie Breindl, Stefan Buchholz, et al.
BMC Cancer|September 26, 2013
The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patientsAnna Machleidt, Stefan Buchholz, Simone Diermeier-Daucher, et al.
Breast Cancer Research : BCR|July 24, 2009
Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancerAndrea Sassen, Simone Diermeier-Daucher, Manuela Sieben, et al.
International Journal of Molecular Medicine|September 30, 2010
Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cellsSabina Berezowska, Simone Diermeier-Daucher, Gero Brockhoff, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|February 24, 2009
Cell type specific applicability of 5-ethynyl-2'-deoxyuridine (EdU) for dynamic proliferation assessment in flow cytometrySimone Diermeier-Daucher, Scott T Clarke, Dani Hill, et al.
Breast Cancer Research : BCR|November 22, 2018
HER4 expression in estrogen receptor-positive breast cancer is associated with decreased sensitivity to tamoxifen treatment and reduced overall survival of postmenopausal womenAnja Kathrin Wege, Dominik Chittka, Stefan Buchholz, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Current Protocols in Cell Biology|September 21, 2010
Dynamic proliferation assessment in flow cytometrySimone Diermeier-Daucher, Gero Brockhoff
Current Protocols in Cytometry|September 5, 2008
Flow cytometric FRET analysis of ErbB receptor tyrosine kinase interactionSimone Diermeier-Daucher, Gero Brockhoff
Annals of the New York Academy of Sciences|July 4, 2008
Flow cytometric FRET analysis of erbB receptor interaction on a cell-by-cell basisSimone Diermeier-Daucher, Max Hasmann, Gero Brockhoff
Mabs|July 24, 2012
Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signalingSimone Diermeier-Daucher, Olaf Ortmann, Stefan Buchholz, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|July 26, 2011
Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factorsSimone Diermeier-Daucher, Stefanie Breindl, Stefan Buchholz, et al.
BMC Cancer|September 26, 2013
The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patientsAnna Machleidt, Stefan Buchholz, Simone Diermeier-Daucher, et al.
Breast Cancer Research : BCR|July 24, 2009
Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancerAndrea Sassen, Simone Diermeier-Daucher, Manuela Sieben, et al.
International Journal of Molecular Medicine|September 30, 2010
Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cellsSabina Berezowska, Simone Diermeier-Daucher, Gero Brockhoff, et al.
Cytometry. Part a : the Journal of the International Society for Analytical Cytology|February 24, 2009
Cell type specific applicability of 5-ethynyl-2'-deoxyuridine (EdU) for dynamic proliferation assessment in flow cytometrySimone Diermeier-Daucher, Scott T Clarke, Dani Hill, et al.
Breast Cancer Research : BCR|November 22, 2018
HER4 expression in estrogen receptor-positive breast cancer is associated with decreased sensitivity to tamoxifen treatment and reduced overall survival of postmenopausal womenAnja Kathrin Wege, Dominik Chittka, Stefan Buchholz, et al.
Pageof 2